🇺🇸 FDA
Pipeline program

CORT125134

CORT125134-451

Phase 2 small_molecule completed

Quick answer

CORT125134 for Cushing's Syndrome is a Phase 2 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
CORCEPT THERAPEUTICS INC
Indication
Cushing's Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials